Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Defining the p53 DNA-binding domain/Bcl-x(L)-binding interface using NMR.

Andrew M Petros1, Angelo Gunasekera, Nan Xu

  • 1Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Rd., R46Y, AP10, Abbott Park, IL 60064, USA. andrew.petros@abbott.com

FEBS Letters
|February 13, 2004
PubMed
Summary

The tumor suppressor p53 directly interacts with Bcl-x(L) and Bcl-2 proteins, inducing apoptosis. This interaction occurs at the DNA-binding site of p53 and can be blocked by the Bad protein.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of KLHL12 Ligands Using Fragment-Based Methods.

Journal of medicinal chemistry·2026
Same author

Identification of ligands for E3 ligases with restricted expression using fragment-based methods.

RSC chemical biology·2025
Same author

Discovery of Macrocyclic Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors that Demonstrate Potent Cellular Efficacy and In Vivo Activity in a Mouse Solid Tumor Xenograft Model.

Journal of medicinal chemistry·2025
Same author

Beyond Isotopic Labeling: Expanding the Reach of Protein-Detect NMR in Lead Discovery.

ACS medicinal chemistry letters·2025
Same author

Discovery of a Myeloid Cell Leukemia 1 (Mcl-1) Inhibitor That Demonstrates Potent <i>In Vivo</i> Activities in Mouse Models of Hematological and Solid Tumors.

Journal of medicinal chemistry·2024
Same author

Efficiently driving protein-based fragment screening and lead discovery using two-dimensional NMR.

Journal of biomolecular NMR·2022

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Cell Biology

Background:

  • The tumor suppressor protein p53 has both transcription-dependent and independent roles in suppressing tumors.
  • The transcription-independent mechanisms, particularly p53's direct induction of apoptosis via mitochondrial permeabilization, are less understood.
  • p53 interacts with anti-apoptotic proteins Bcl-x(L) and Bcl-2, a key step in initiating apoptosis.

Purpose of the Study:

  • To elucidate the molecular mechanism of transcription-independent tumor suppression by p53.
  • To identify the specific interaction sites between p53 and Bcl-x(L).
  • To investigate the role of the BH3 domain of Bad in modulating the p53-Bcl-x(L) interaction.

Main Methods:

  • Nuclear magnetic resonance (NMR) spectroscopy was employed to study protein-protein interactions.

Related Experiment Videos

  • The study focused on the complexation between the DNA-binding region of p53 and Bcl-x(L).
  • The effect of a peptide derived from the BH3 region of Bad on the p53-Bcl-x(L) complex was assessed.

    • Main Results:

    • NMR analysis revealed that p53 binds to Bcl-x(L) using the same region it uses to bind DNA.
    • The binding site on Bcl-x(L) was mapped to specific regions including alpha-helices and loops.
    • The interaction between p53 and Bcl-x(L) was inhibited by the BH3 peptide from Bad.

    Conclusions:

    • p53's transcription-independent tumor suppressor activity involves direct interaction with anti-apoptotic proteins like Bcl-x(L).
    • The DNA-binding domain of p53 is crucial for this interaction, highlighting a dual role for this region.
    • The Bad BH3 domain peptide competitively inhibits this interaction, suggesting a potential therapeutic target for modulating apoptosis.